S&P 500   3,853.74
DOW   31,171.35
QQQ   324.48
S&P 500   3,853.74
DOW   31,171.35
QQQ   324.48
S&P 500   3,853.74
DOW   31,171.35
QQQ   324.48
S&P 500   3,853.74
DOW   31,171.35
QQQ   324.48
Log in
NYSE:ABT

Abbott Laboratories Stock Forecast, Price & News

$113.21
+0.64 (+0.57 %)
(As of 01/20/2021 03:10 PM ET)
Add
Compare
Today's Range
$112.19
Now: $113.21
$113.53
50-Day Range
$106.32
MA: $108.93
$112.15
52-Week Range
$61.61
Now: $113.21
$115.14
Volume136,975 shs
Average Volume5.14 million shs
Market Capitalization$200.65 billion
P/E Ratio59.90
Dividend Yield1.62%
Beta0.83
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

MarketRank

Overall MarketRank

2.56 out of 5 stars

Medical Sector

7th out of 1,928 stocks

Pharmaceutical Preparations Industry

3rd out of 774 stocks

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100
Employees107,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$5.07 per share
Book Value$17.70 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Outstanding Shares1,772,362,000
Market Cap$200.65 billion
Next Earnings Date1/27/2021 (Confirmed)
OptionableOptionable
$113.21
+0.64 (+0.57 %)
(As of 01/20/2021 03:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by Coronavirus?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 45.1% and is now trading at $113.29.
View which stocks have been most impacted by COVID-19
.

Is Abbott Laboratories a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Abbott Laboratories?

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Abbott Laboratories' CEO?

538 employees have rated Abbott Laboratories CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Abbott Laboratories' employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories
.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, October, 21st. The healthcare product maker reported $0.98 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.90 by $0.08. The healthcare product maker earned $8.85 billion during the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The company's revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.84 earnings per share.
View Abbott Laboratories' earnings history
.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, December 11th. Shareholders of record on Friday, January 15th will be paid a dividend of $0.45 per share on Tuesday, February 16th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date of this dividend is Thursday, January 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.36.
View Abbott Laboratories' dividend history
.

Is Abbott Laboratories a good dividend stock?

Abbott Laboratories pays an annual dividend of $1.80 per share and currently has a dividend yield of 1.62%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.10% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

What price target have analysts set for ABT?

16 equities research analysts have issued twelve-month price objectives for Abbott Laboratories' stock. Their forecasts range from $94.00 to $130.00. On average, they anticipate Abbott Laboratories' share price to reach $115.69 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for Abbott Laboratories
or view Wall Street analyst' top-rated stocks.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Exec. Chairman (Age 66, Pay $6.97M)
  • Mr. Robert B. Ford, CEO, Pres, COO & Director (Age 47, Pay $2.63M)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 42, Pay $1.67M)
  • Ms. Lisa D. Earnhardt, Exec. VP of Medical Devices (Age 51, Pay $1.33M)
  • Mr. Robert E. Funck Jr., Exec. VP of Fin. & CFO (Age 60)
  • Mr. Scott Michael Leinenweber, VP of Investor Relations, Licensing & Acquisitions (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • James E. Young, VP and Chief Ethics & Compliance Officer
  • Ms. Melissa Brotz, VP of Public Affairs & Corp. Marketing
  • Ms. Elaine R. Leavenworth, Sr. VP and Chief Marketing & External Affairs Officer (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.10%), Gateway Investment Advisers LLC (0.04%), Welch & Forbes LLC (0.04%), Huntington National Bank (0.03%), Gofen & Glossberg LLC IL (0.03%) and Park National Corp OH (0.03%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories
.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Hexavest Inc., Gateway Investment Advisers LLC, Rhenman & Partners Asset Management AB, State of Alaska Department of Revenue, Autus Asset Management LLC, Lantz Financial LLC, and Chesley Taft & Associates LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories
or view top insider-selling stocks.

Which major investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Tandem Investment Advisors Inc., Journey Advisory Group LLC, Hendley & Co. Inc., IFM Investors Pty Ltd, Bath Savings Trust Co, Louisiana State Employees Retirement System, and Grant GrossMendelsohn LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories
or or view top insider-buying stocks.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $113.29.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $200.79 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.